ProCore Advisors’s AbbVie ABBV Stock Holding History

ProCore Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,010	Closed	-$231K	–	74
2025 Q4	$231K	Buy	+1,010	New	+$230K	0.24%	75

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ProCore Advisors's ABBV Position: Q1 2026 in Review

ProCore Advisors sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 1,010 shares — an estimated $231K sold.

ProCore Advisors first reported a position in ABBV in Q4 2025 and held it in 1 quarter. The position peaked at $231K in Q4 2025. 4,088 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

ProCore Advisors reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
ProCore Advisors sold 1,010 AbbVie shares in Q1 2026, an estimated $231K.
ProCore Advisors first reported a position in AbbVie in Q4 2025 and held it in 1 quarter.
ProCore Advisors's AbbVie position peaked at $231K in Q4 2025.
4,088 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on ProCore Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.